48.1 F
New York
Monday, November 30, 2020

Axovant [NASDAQ: AXGT] Inks AXO-LENTI-PD Supply Deal With Oxford Biomedica

Must read

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...

Athene Enters Into An Agreement With Hertz To Buy Donlen Corp.

Athene Holdings ltd. entered into a deal to buy Donlen corporation from Hertz Global Holdings Inc. Hertz's fully own Donlen Corporation. The stock...

Verizon [NYSE: VZ] Announced to acquire Tracfone for $6.25 billion.

Verizon Communication Inc. declared that it penned down a deal with America Movil to purchase Tracfone for $6.25B. The companies came to terms...

Axovant Gene Therapies Ltd. [NASDAQ: AXGT] disclosed today that its subsidiary has inked a three-year Clinical Supply Agreement (CSA) with Oxford Biomedica Plc [LSE: OXB].

The CSA between the two firms in June 2018 for a worldwide licensing agreement for the Parkinson’s disease gene therapy program OXB-102, now called AXO-Lenti-PD. AXO-Lenti-PD is an investigational gene therapy developed for the treatment of Parkinson’s disease.

As per the deal, to continue the ongoing and future clinical development of AXO-Lenti-PD Oxford Biomedica will make GMP batches for AXGT. Axovant Gene Therapies is currently directing the SUNRISE-PD phase 2 Trial with AXO-Lenti-PD.

Shares of Axovant had traded up 0.34% and up +0.01 during the trading of Thursday. It has a day low range of $2.93 and a day high range of $3.03. If we look at its liquidity, the quick ratio for Axovant Gene Therapies is 2.70. Similarly, its current ratio is the same as the quick ratio.

Continuing to look at its profitability, its return on assets (ROA) is -92.70% and return on equity (ROE) is -257.10%. Axovant has reported the income of -72.60 million. It has total market capitlization of 125.79 million.

During the period of 52-week, this company’s stocks have fluctuated between the low of $1.41 and a high of $8.08. It has increased 112.06% from its 52-weeks low and moved down -63.00% from its 52-weeks high. Axovant is looking forward to work with Oxford Biomedica for the development of AXO-Lenti-PD.

More articles

Latest article

ViacomCBS [NASDAQ: VIAC] Agreed To Sell Simon And Schuster For $2.175 Billion In Cash

ViacomCBS Inc. declared that it entered into an agreement with Penguin Random House LCC to sell Simon and Schuster. It will be sold...

IBM [NYSE: IBM] Plans To Cut Down 20% Of Its Workforce

International business machines Corp. declared that the company is preparing to cut down 10,000 jobs in Europe which makes it’s 20% of the...

Ford [NYSE: F ] Booked Ultra-Cold Freezers To Ensure Autoworkers Access To The Covid-19 Vaccine

Ford Motors Co. revealed recently that to stock Pfizer Inc Covid-19 vaccine securely, it has requested 12 of the ultra-cold freezer. The automaker...

Transdigm [NYSE: TDG] Enters Into An Agreement To Buy Cobham Aero Connectivity

Transdigm group incorporation , the global aircraft component manufacturer and provider declared the acquisition of Cobham Aero Connectivity, the top supplier of antennas and...

LCI Industries’ [NYSE: LCII] Subsidiary Lippert Components Acquires Challenger Door

LCI Industries has revealed that its unit Lippert Components has completed the acquisition of Challenger Door, Inc. This acquisition will provide the opportunity...

Blackstone Group [NYSE: BX] Finalizes Recapitalization Of BioMed Realty

The Blackstone Group Inc. has disclosed today that Blackstone Real Estate Partners VIII L.P.  has executed the deal related to BioMed Realty. The...

Pfizer-BioNTech’s COVID19 Vaccine Candidate Acheive 95% Success

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have disclosed Wednesday that their COVID-19 vaccine candidate, BNT162b2, has shown a 95% efficacy rate...

Scienjoy [NASDAQ: SJ] Inks Agreement With China Mobile

Scienjoy Holdings Corporation has revealed today that it has inked a cooperative agreement with China Mobile on November 1, 2020. The company disclosed...